All lobbying filings

INNOVATIVE FEDERAL STRATEGIES, LLC

Lobbying for ACURX PHARMACEUTICALS, INC. · biopharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New York · House · Senate · $30,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 6

HR 4026
POST Act of 2025
S 2572
Department of Defense Appropriations Act, 2026
HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
S 2296
National Defense Authorization Act for Fiscal Year 2026

Lobbying activity 2

Budget/Appropriations

H.R.4026/S.2572, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.5304/S.2587, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.

Defense

H.R.3838/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.